News

One of the objectives of our team is to inform you about new treatments. You can catch up on the last news in the latest press release by Summit Therapeutics company about ezutromid, a utrophin [...]

Following positive results obtained in Phase I/II trial of SRP-4053 (Golodirsen), Sarepta Therapeutics has announced a plan to submit a new drug application (NDA) for accelerated approval of [...]

Solid Biosciences announces a clinical hold on SGT-001 microdystrophin gene transfer the clinical Phase I/II clinical trial for Duchenne muscular dystrophy.  Solid Biosciences Inc. announced it [...]

What’s it like to live with DMD? As a parent, to face the reality that your child has a fatal disease? As a person with DMD, to face an inevitable, premature death in your twenties? As a sibling, [...]

Today, PTC Therapeutics, Inc, announced that the Office of New Drugs of the U.S. Food and Drug Administration has reiterated the FDA’s prior position and denied PTC’s appeal of the [...]

Our web short documentary series, “Portrait of Duchenne Canada”, will be coming son!  We will present the experiences of families and children with DMD across Canada.What’s it like to [...]

February is the Rare Disease Month. Because it manifests itself only rarely, Duchenne muscular dystrophy (DMD) falls within the rare diseases category. It is also a treatment orphan disease. [...]

Today, Summit Therapeutics announced positive 24-week interim data from PhaseOut DMD (Phase 2 clinical trial of the utrophin modulator ezutromid). This data showed a significant reduction in [...]

Bruce Babington, an Osteopath, based in Ste-Agathe-des-Monts, Québec, is taking on the challenge of cycling across Canada in July 2018. He was inspired by his patient, Anakin Lacasse, who is [...]

Last week we had the privilege to meet in person with the team at their headquarter in Boston. They presented their very robust preclinical trial data suggesting that SGT-001, has the potential [...]